Table 1 Correlations of TP53 mutation status with clinicopathological characteristics (A) and IHC4 risk group and PAM50 subtypes (B).

From: TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays

  1. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2. *Neoadjuvant and/or adjuvant therapy.
Back to article page